RADIUM RA-223 CATION

Details

Stereochemistry	ACHIRAL
Molecular Formula	Ra
Molecular Weight	223.0185
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

[223Ra++]

InChI

InChIKey=PZDJSXWIQXZUBJ-OIOBTWANSA-N

InChI=1S/Ra/q+2/i1-3

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203971s007lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23653243; http://www.ncbi.nlm.nih.gov/pubmed/?term=23977665

Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Castrate-resistant prostate cancer 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203971s007lbl.pdf	Primary		Approved 8429	XOFIGO Approved Use Xofigo is an alpha particle-emitting radioactive thera peutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptoma tic bone metastases and no known visceral metastatic disease Launch Date 1.36857597E12

PubMed

Title	Date	PubMed
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.	2008 Mar	18368304
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.	2013 Feb	23000088
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.	2013 Sep	23653243

Patents

Sample Use Guides

In Vivo Use Guide

The dose regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.

Route of Administration: Intravenous

In Vitro Use Guide

Radium-223 dichloride showed a dose-dependent inhibition of MDA-MB-231(SA) breast cancer cell proliferation at concentrations of 400, 800 and 1600 Bq/mLcompared to the control in a 5-day in vitro proliferation assay

Name

Type

Language

RADIUM RA-223 CATION

Common Name

English

RADIUM, ISOTOPE OF MASS 223 (223RA2+)

Common Name

English

RADIUM-223 ION(2+)

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000187053